Recherche translationnelle en santé,
technologie pour la santé et recherche clinique
- > Equipe DEVIN
Travaille sur
- > Antibody anti-PDL1 radiolabelling with 89Zr : feasibility and in vitro characterization
Anis KRACHE, Charlotte FONTAN, Pierre PAYOUX, Anne-Sophie SALABERT, Mélanie WHITE-KONING
4th Nuclear Technologies for Health Symposium, 13-14 février 2020, Nantes
Abstracts rédigés ou co-rédigés
- > 32- Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1Neurology. 2024 May;102(10):e209326. doi: 10.1212/WNL.0000000000209326.
Barateau L, Krache A, Da Costa A, Lecendreux M, Debs R, Chenini S, Arlicot N, Vourc’h P, Evangelista E, Alonso M, Salabert AS, Silva S, Béziat S, Jaussent I, Mariano-Goulart D, Payoux P, Dauvilliers Y.
- > 9- Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.Front Med (Lausanne). 2022 Jan 31;8:741855. doi: 10.3389/fmed.2021.741855.
Krache A, Fontan C, Pestourie C, Bardiès M, Bouvet Y, Payoux P, Chatelut E, White-Koning M, Salabert AS.